Aficamten对梗阻性肥厚型心肌病心脏结构及功能的影响:SEQUOIA-HCM CMR亚研究
SEQUOIA-HCM的CMR亚研究纳入57例症状性oHCM患者,随机接受aficamten(5-20 mg)或安慰剂治疗24周,50例完成基线与24周CMR。与安慰剂相比,aficamten显著降低LV质量指数、最大LV壁厚度、左房容积指数、原生T1时间、细胞外容积分数和心肌细胞质量指数,但LV腔容积、替代性纤维化或细胞外容积无显著变化。提示aficamten可改善心脏重构。
要点
- Aficamten治疗24周显著降低oHCM患者LV质量指数、壁厚度和左房容积。
- Aficamten未显著改变LV腔容积、LGE质量或细胞外容积。
- CMR亚组样本量小(50例完成),结论需更大样本验证。
核心结论
- 与安慰剂相比,aficamten治疗24周在oHCM患者中产生有利的心脏重构。
- LV质量、壁厚度和左房大小的改善可能长期减少心衰和房颤等心血管事件。
研究设计与样本
- SEQUOIA-HCM为3期双盲、安慰剂对照试验,成人症状性oHCM随机1:1接受aficamten(5-20 mg)或安慰剂24周。
- 282例随机患者中57例(20%)参与CMR亚研究,50例(88%)完成基线与24周CMR。
- 50例中21例接受aficamten,29例接受安慰剂;图像由核心实验室盲法分析。
主要发现
- 与安慰剂相比,aficamten组LV质量指数最小二乘均值差为-15 g/m2(95%CI:-25至-6 g/m2;P=0.001)。
- 最大LV壁厚度差为-2.1 mm(95%CI:-3.1至-1.1 mm;P<0.001)。
- 左房容积指数差为-13 mL/m2(95%CI:-19至-7 mL/m2;P<0.001)。
- 原生T1时间差为-37 ms(95%CI:-69至-5 ms;P=0.026),细胞外容积分数指数差为-3.9 g/m2(95%CI:-7.0至-0.9 g/m2;P=0.014),心肌细胞质量指数差为-14 g/m2(95%CI:-23至-4 g/m2;P=0.004)。
- LV腔容积、LGE质量(-0.7 g;95%CI:-2.9至1.6 g;P=0.54)和细胞外容积(0.7%;95%CI:-2.2%至3.6%;P=0.61)无显著变化。
临床怎么用
- 对于症状性oHCM患者,aficamten可能通过改善心脏重构(尤其是LV质量、壁厚度和左房大小)带来临床获益。
- CMR可用于监测aficamten治疗后的心脏结构逆转,但需结合临床终点进一步验证。
局限性
- CMR亚研究样本量较小(50例完成),可能影响统计效能和结果外推。
- 随访仅24周,长期对心血管事件的影响尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and stroke. Aficamten is a next-in-class cardiac myosin inhibitor that reduces outflow tract obstruction by modulating cardiac contractility, with the potential to reverse pathological remodeling and, in turn, reduce cardiovascular events. OBJECTIVES: This study sought to investigate the effect of aficamten on cardiac remodeling compared with placebo using cardiovascular magnetic resonance (CMR) and its association with key clinical endpoints in the SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) CMR substudy. METHODS: SEQUOIA-HCM was a phase 3 double-blind, placebo-controlled trial for adults with symptomatic oHCM who were randomized 1:1 to 24 weeks of aficamten (dose range: 5-20 mg) or placebo. Eligible participants were offered enrollment in the CMR substudy with studies performed at baseline and week 24. Image analysis was performed in a blinded fashion by a core laboratory. RESULTS: Of the 282 randomized patients, 57 (20%) participated in the substudy, and of those, 50 (88%) completed both baseline and week 24 CMR. Baseline characteristics of the CMR cohort were similar to the overall study population. Of these 50 patients, 21 received aficamten and 29 received placebo. Relative to placebo, patients receiving aficamten demonstrated significant reductions (Δ least-squares mean) in LV mass index (-15 g/m2; 95% CI: -25 to -6 g/m2; P = 0.001), maximal LV wall thickness (-2.1 mm; 95% CI: -3.1 to -1.1 mm; P < 0.001), left atrial volume index (-13 mL/m2; 95% CI: -19 to -7 mL/m2; P < 0.001), native T1 relaxation time (-37 ms; 95% CI: -69 to -5 ms; P = 0.026), indexed extracellular volume fraction (-3.9 g/m2; 95% CI: -7.0 to -0.9 g/m2; P = 0.014), and indexed myocyte mass (-14 g/m2; 95% CI: -23 to -4 g/m2; P = 0.004), while there were no significant changes in LV chamber volumes, LV replacement fibrosis (late gadolinium enhancement mass -0.7 g; 95% CI: -2.9 to 1.6 g; P = 0.54), or extracellular volume (0.7%; 95% CI: -2.2% to 3.6%; P = 0.61). CONCLUSIONS: The CMR substudy of SEQUOIA-HCM demonstrated that treatment with aficamten relative to placebo for 24 weeks resulted in favorable cardiac remodeling. These changes, particularly with regard to LV mass, wall thickness, and left atrial size, could potentially lead to reduced cardiovascular events including heart failure and atrial fibrillation with longer follow-up. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
引用
- Masri A, Cardoso RN, Abraham TP, et al. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024. PMID: 39217563. doi:10.1016/j.jacc.2024.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。